All In Biotech

Drug Trial Radar · NCT05249127

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Apr 11, 2022

Primary completion

Aug 8, 2023

Study completion Aug 8, 2023

Sponsor

Lead sponsor
Clarity Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.

Conditions

  • Biochemical Recurrence of Malignant Neoplasm of Prostate

Interventions

  • 64Cu-SAR-bisPSMADrug

    64Cu-SAR-bisPSMA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: up to 7 days post injection
  2. Participant-level Correct Detection Rate (CDR)- Day 0Time frame: Day 0 (1- 4 hours) post injection
  3. Participant-level CDR- Day 1Time frame: Day 1 (24+/-6 Hours) post injection
  4. Region-level Positive Predictive Value (PPV)- Day 0Time frame: Day 0 (1- 4 hours)
  5. Region-level PPV- Day 1Time frame: Day 1 (24 +/- 6 hours)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Tower Urology

    Los Angeles, California

  • GU Research Network

    Omaha, Nebraska

  • New Mexico Cancer Center

    Albuquerque, New Mexico

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.